ImmunisBio-SmartCellLab, Entry into Indochina Cell Therapy Business

Cooperation between Laos Lansang Holdings and Korao Group

ImmunisBio and SmartCellLab announced on the 30th that they have signed a contract to join a joint venture with Laos Lansang Holdings to improve and support the healthcare system in the Indochina region.

Korao Group-Lansang Holdings has agreed to collaborate in supplying advanced regenerative medicine and advanced medical systems, such as cell therapy products, to the region. ImmunisBio and SmartCellLab, which research advanced regenerative medicine, will supply advanced regenerative medical systems centered in Laos and throughout Indochina. They plan to establish medical facilities where needed and help ensure easy access to the medical system for everyone.

They will establish hospitals providing advanced medical care and introduce cutting-edge regenerative treatments such as NK cell therapy, stem cell therapy, and progenitor cell therapy within the hospitals, along with advanced medical fields from Korea and overseas. They will distribute these throughout Laos to promote regional healthcare access for residents in areas lacking medical facilities. Based on the Laos case, they plan to expand to regions including Myanmar, Cambodia, Vietnam, and Thailand.

ImmunisBio and SmartCellLab will transfer their excellent cell therapy development and manufacturing technologies to the joint venture to promote the supply of cell therapy products in Laos and the Indochina region. With full support from the joint venture partners Lansang Holdings and Korao Group, they will actively participate in improving healthcare business in Indochina.

Kang Jeonghwa, CEO of ImmunisBio, said, "We are pleased that the establishment of the medical joint venture has taken a step forward in the regenerative medical environment in Southeast Asia," adding, "We will strive to expand cell therapy products in the Southeast Asian region through the synergy of both parties."

Hwang Seonghwan, CEO of SmartCellLab, explained, "We are glad that cell therapy products are helping patient treatment in countries like Laos," and added, "We hope that Korea’s excellent medical system will be widely introduced and jointly advanced through the healthcare environment improvement projects promoted by our joint venture partners."

ImmunisBio is currently conducting Phase 2 clinical trials of NK cell therapy products domestically. They are actively entering overseas treatment markets, expanding into Japan, Malaysia, and Vietnam, and pursuing an initial public offering (IPO). SmartCellLab is conducting the world’s first clinical trial of cartilage progenitor cell therapy through progenitor stem cell research.